8Indexed trials
drug · Product Intelligence
Paclitaxel
Pipeline Intelligence
Paclitaxel: 8 indexed trials, 3 sponsors; 14 linked Orange Book patents and 20 FDA-linked events where matched.
3Sponsors
14Orange Book patent links
20FDA-linked events
Development evidence
NCT02134067Taiho Oncology, Inc. · epilepsyPHASE1
NCT02564263Merck Sharp & Dohme LLC · parkinsonsPHASE3
NCT02622074Merck Sharp & Dohme LLC · parkinsonsPHASE1
NCT03348904Incyte Corporation · parkinsonsPHASE3
NCT06788912Merck Sharp & Dohme LLC · parkinsonsPHASE2
NCT06952504Merck Sharp & Dohme LLC · parkinsonsPHASE3
NCT06966700Merck Sharp & Dohme LLC · parkinsonsPHASE3
NCT07216703Merck Sharp & Dohme LLC · parkinsonsPHASE3
FDA / patent evidence
9511046*PEDABRAXANE · app 0216602034-07-12
9511046ABRAXANE · app 0216602034-01-12
9393318*PEDABRAXANE · app 0216602032-09-04
9597409*PEDABRAXANE · app 0216602032-09-04
9393318ABRAXANE · app 0216602032-03-04
9597409ABRAXANE · app 0216602032-03-04
8034375*PEDABRAXANE · app 0216602027-02-13
9101543*PEDABRAXANE · app 0216602026-08-21
7758891*PEDABRAXANE · app 0216602026-08-21
8268348*PEDABRAXANE · app 0216602026-08-21
8034375ABRAXANE · app 0216602026-08-13
7758891ABRAXANE · app 0216602026-02-21
Regulatory context
FDA_APPROVALPACLITAXEL · 2025-08-19
FDA_APPROVALPACLITAXEL · 2025-05-15
FDA_APPROVALPACLITAXEL · 2025-04-10
FDA_APPROVALPACLITAXEL · 2024-10-08
FDA_APPROVALPACLITAXEL · 2022-10-20
FDA_APPROVALPACLITAXEL · 2022-07-27
FDA_APPROVALPACLITAXEL · 2020-08-24
FDA_APPROVALPACLITAXEL · 2018-08-17
FDA_APPROVALPACLITAXEL · 2016-08-23
FDA_APPROVALPACLITAXEL · 2011-09-29
FDA_APPROVALPACLITAXEL · 2009-12-09
FDA_APPROVALPACLITAXEL · 2007-12-26
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.